MX2016014633A - Nuevos derivados de cath2. - Google Patents

Nuevos derivados de cath2.

Info

Publication number
MX2016014633A
MX2016014633A MX2016014633A MX2016014633A MX2016014633A MX 2016014633 A MX2016014633 A MX 2016014633A MX 2016014633 A MX2016014633 A MX 2016014633A MX 2016014633 A MX2016014633 A MX 2016014633A MX 2016014633 A MX2016014633 A MX 2016014633A
Authority
MX
Mexico
Prior art keywords
derivatives
cath2
new
inverso
truncated
Prior art date
Application number
MX2016014633A
Other languages
English (en)
Inventor
Peter HAAGSMAN Hendrik
Van Dijk Albert
Johannes Adrianus Veldhuizen Edwin
Original Assignee
Univ Utrecht Holding Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Utrecht Holding Bv filed Critical Univ Utrecht Holding Bv
Publication of MX2016014633A publication Critical patent/MX2016014633A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/465—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from birds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Fodder In General (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención proporciona nuevos derivados de CATH2 o CMAP27, una de las catelicidinas. Estos derivados comprenden péptidos truncados N-terminales, péptidos cíclicos, variantes de D-aminoácidos de CATH2 y sus derivados truncados, derivados inversos y retro-inversos de CATH2. Estos derivados son útiles como antiinfecciosos, en vacunas, y especialmente para aplicaciones in ovo. Además, para los derivados anteriores y también para los derivados truncados C-terminales ya conocidos, se han descrito nuevas funciones de inmunización que son particularmente ventajosas para tratamientos profilácticos.
MX2016014633A 2014-05-09 2015-05-08 Nuevos derivados de cath2. MX2016014633A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14167718 2014-05-09
PCT/NL2015/050323 WO2015170984A1 (en) 2014-05-09 2015-05-08 New cath2 derivatives

Publications (1)

Publication Number Publication Date
MX2016014633A true MX2016014633A (es) 2017-04-27

Family

ID=50685785

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016014633A MX2016014633A (es) 2014-05-09 2015-05-08 Nuevos derivados de cath2.

Country Status (9)

Country Link
US (3) US10829524B2 (es)
EP (1) EP3140315A1 (es)
JP (2) JP6676544B2 (es)
CN (1) CN106488929B (es)
AU (2) AU2015256729B2 (es)
CA (2) CA2948455C (es)
MX (1) MX2016014633A (es)
RU (1) RU2726124C2 (es)
WO (1) WO2015170984A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6676544B2 (ja) * 2014-05-09 2020-04-08 ユニベルシテイト、ユトレヒト、ホールディング ベスローテン、フェンノートシャップＵｎｉｖｅｒｓｉｔｅｉｔ Ｕｔｒｅｃｈｔ Ｈｏｌｄｉｎｇ Ｂ．Ｖ． 新しいｃａｔｈ２誘導体。
CN109535227B (zh) * 2018-12-18 2020-10-02 西安市儿童医院 抗菌肽、抗菌肽制备方法、抗菌组合物、抗菌方法和应用
CN110128544B (zh) * 2019-04-03 2020-12-01 中国农业大学 一种具有免疫调节和抗炎功能的杂合肽及其制备方法与应用
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
EP4262842A1 (en) 2020-12-18 2023-10-25 Universiteit Utrecht Holding B.V. Cath2 derivatives for stimulating innate immune memory
US20240165200A1 (en) * 2021-02-05 2024-05-23 Universiteit Utrecht Holding B.V. Cath2 and derivatives for inhibiting streptococcus suis
AR126731A1 (es) * 2021-08-05 2023-11-08 Zoetis Services Llc Composiciones y métodos para tratar la mastitis
WO2023114564A1 (en) * 2021-12-15 2023-06-22 Zoetis Services Llc Compositions and methods for activating innate immunity

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4040388A (en) 1976-02-27 1977-08-09 Agrimatic Corporation Method and apparatus for automatic egg injection
US4593646A (en) 1982-06-01 1986-06-10 Agrimatic Corporation Egg injection method and apparatus
US4469047A (en) 1983-10-25 1984-09-04 Miller Gary E Apparatus and method for injecting eggs
US4681063A (en) 1986-07-02 1987-07-21 Embrex Inc. High speed automated injection system for avian embryos
US6495146B1 (en) * 1995-06-07 2002-12-17 Pfizer Incorporated In ovo vaccination against coccidiosis
DK0996451T3 (da) 1997-05-20 2005-05-23 Galenica Pharmaceuticals Inc Triterpensaponinanaloger med adjuvans- og immunstimulatorisk aktivitet
DE60100814T2 (de) * 2000-06-08 2004-07-01 Intercell Biomedizinische Forschungs- Und Entwicklungs Gmbh Immunstimulierende oligodeoxynukleotide
AU8981301A (en) * 2000-08-17 2002-02-25 Cistem Biotechologies Gmbh A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
WO2005053737A1 (en) * 2003-12-03 2005-06-16 Pfizer Products Inc. In ovo vaccination of campylobacter in avian species
US20080119405A1 (en) * 2005-12-02 2008-05-22 The Board Of Regents For Oklahoma State University Fowlicidins and Methods of Their Use
ES2548767T3 (es) * 2007-01-16 2015-10-20 The Regents Of The University Of California Nuevos péptidos antimicrobianos
CA2696833A1 (en) 2007-07-15 2009-01-22 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
PT3150627T (pt) * 2009-02-13 2019-02-18 Univ Utrecht Holding Bv Péptidos antimicrobianos com base em cmap27
RU2458526C1 (ru) * 2011-03-28 2012-08-20 Общество с ограниченной ответственностью "Поливит" (ООО "Поливит") Пробиотическая кормовая добавка для сельскохозяйственных птиц и пушных зверей
JP6676544B2 (ja) * 2014-05-09 2020-04-08 ユニベルシテイト、ユトレヒト、ホールディング ベスローテン、フェンノートシャップＵｎｉｖｅｒｓｉｔｅｉｔ Ｕｔｒｅｃｈｔ Ｈｏｌｄｉｎｇ Ｂ．Ｖ． 新しいｃａｔｈ２誘導体。

Also Published As

Publication number Publication date
JP2017518976A (ja) 2017-07-13
RU2016144509A3 (es) 2019-02-05
AU2015256729A1 (en) 2016-11-24
JP6676544B2 (ja) 2020-04-08
RU2726124C2 (ru) 2020-07-09
JP2020109109A (ja) 2020-07-16
WO2015170984A1 (en) 2015-11-12
US20210246177A1 (en) 2021-08-12
CA2948455A1 (en) 2015-11-12
EP3140315A1 (en) 2017-03-15
RU2016144509A (ru) 2018-06-13
CN106488929B (zh) 2021-08-24
US10829524B2 (en) 2020-11-10
AU2019283922A1 (en) 2020-01-30
US20170145065A1 (en) 2017-05-25
AU2015256729B2 (en) 2019-09-19
CA2948455C (en) 2023-09-19
US11603391B2 (en) 2023-03-14
CA3207425A1 (en) 2015-11-12
CN106488929A (zh) 2017-03-08
US20230382961A1 (en) 2023-11-30

Similar Documents

Publication Publication Date Title
MX2016014633A (es) Nuevos derivados de cath2.
AU2019284081A1 (en) Food compositions comprising recombinant milk proteins and methods of producing the same
TN2017000085A1 (en) Polypeptide having a polyester degrading activity and uses thereof
AU2015286723B2 (en) Influenza virus vaccines and uses thereof
MX2017008449A (es) Polipeptido de pirina y modulacion inmune.
WO2014113490A3 (en) Immunogenic wt-1 peptides and methods of use thereof
WO2016046234A3 (en) Recombinant phe-free proteins for use in the treatment of phenylketonuria
WO2015027259A3 (de) Polypeptid zur hydrolytischen spaltung von zearalenon und/oder zearalenon-derivaten, isoliertes polynukleotid davon sowie einen zusatzstoff enthaltendes polypeptid, verwendung desselben sowie verfahren
MX2019007152A (es) Peptido novedoso.
EP3936141A3 (en) Anti-senescence compounds and uses thereof
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
MX2021001460A (es) Metodos y composiciones para secrecion de polipeptidos heterologos.
WO2015132675A3 (en) Methods and compositions for modifying the immune response
MX2016011394A (es) Moleculas de andamiaje a base de fibronectina estabilizada.
MX2016014144A (es) Composiciones de proteina concentrada y metodos para su elaboracion y uso.
PH12017500742A1 (en) Statherin peptides
EP3360895A3 (en) Preparation comprising factor viii and von willebrand factor peptides
WO2016058512A8 (zh) 马拉巴石斑鱼Piscidin的改造体抗菌肽及其应用
MX2019003970A (es) Péptidos de arginasa inmunogénicos.
MX2020006510A (es) Peptido novedoso.
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
WO2015107363A3 (en) Mycobacterial antigen composition
MX2017006625A (es) Mutantes de neumolisina y metodos de uso de los mismos.
MX2017008286A (es) Nuevos metodos para el despliegue de peptidos ciclicos en particulas de bacteriofagos.
EP3925968A3 (en) Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell